---
schema_version: "secwatch.filing_event.v1"
accession: "0001831283-22-000012"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2022-03-30T23:59:59+00:00"
generated_at: "2026-06-26T13:56:27.108215+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# LianBio reports Q4 net loss $21.2M; cash $403.2M; mavacamten Phase 3 ongoing

## Summary
- Net loss $21.2M in Q4 2021 vs $12.7M Q4 2020; full-year loss $196.3M vs $139.6M.
- Cash, equivalents, marketable securities $403.2M at Dec 31, 2021; runway through 2023.
- Phase 3 EXPLORER-CN trial of mavacamten initiated in Chinese oHCM patients; Breakthrough Therapy designation granted.
- Infigratinib approved under named patient program for cholangiocarcinoma in Hainan pilot zone.
- Three programs (TP-03, NBTXR3, infigratinib) expected to enter Phase 3 in China by end of 2022.

## SEC filing metadata
- accession: 0001831283-22-000012
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2022-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000183128322000012/0001831283-22-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000183128322000012/lian-20220330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831283-22-000012
- JSON: https://secwatch.observer/filing/0001831283-22-000012.json
- Plain text: https://secwatch.observer/filing/0001831283-22-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.